6533b85dfe1ef96bd12bf21f
RESEARCH PRODUCT
Anticonvulsant effects of carbenoxolone in genetically epilepsy prone rats (GEPRs).
Gareri PietroCondorelli DanieleBelluardo NataleEmilio RussoLoiacono AntonellaVincenza BarresiTrovato-salinaro AngelaTrovato-salinato AngelaMirone Melita BFerreri Ibbadu GuidoGiovambattista De Sarrosubject
MaleAudiogenic seizuremedicine.medical_treatmentGap junctionGEPR-9sCarbenoxoloneSubstantia nigraPharmacologyConnexinConnexinsRats Sprague-DawleyCellular and Molecular NeuroscienceEpilepsyMedicineAnimalsMicroinjectionPharmacologyEpilepsybusiness.industrymedicine.diseaseMotor coordinationRatsAnticonvulsantAnesthesiaSystemic administrationCarbenoxoloneAnticonvulsantsFemalebusinessPars reticulataGEPR-3medicine.drugdescription
Carbenoxolone (CBX), the succinyl ester of glycyrrhetinic acid, is an inhibitor of gap junctional intercellular communication. Systemic administration of CBX was able to decrease the seizure severity score and to increase the latency time of seizure onset in genetically epilepsy prone rats (GEPRs). In particular, intravenous or intraperitoneal administration of carbenoxolone (5-30 mg/kg) produced a dose-dependent and significant reduction in the clonic and tonic phases of the audiogenic seizures in GEPRs. The anticonvulsant doses were not associated with an impairment of motor coordination. The bilateral microinjection of CBX (0.001-0.50 microg/0.5 microl) into the inferior colliculi, the substantia nigra (pars reticulata or compacta) and the inferior olivary complex was able to reduce the seizure severity score in a dose-dependent manner. The anticonvulsant effects were longer lasting after focal microinjection than after systemic administration. No anticonvulsant effects were observed following focal bilateral microinjections of glycyrrhizin into the same brain areas where CBX was shown to be effective.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2004-01-01 | Neuropharmacology |